Will the American Health Care System Thwart the Covid-19 Antiviral Revolution?
New Republic November 19, 2021
New medicines are on the way in the fight against the pandemic, but these life-saving drugs might get trapped in a maze of bad policy.
Is a new dawn breaking in the fight against the global pandemic? Now that two major pharmaceutical firms have filed for emergency use authorization
for new antiviral pills, we may soon have some valuable arrows in our quiver to fight Covid-19. Per company reports, a short course of Merck’s molnupiravir regimen reduces hospitalizations among infected patients by 50
percent; Pfizer’s Paxlovid curbed admissions by an eye-popping 89 percent
—and neither treatment group reported any deaths. The Biden administration has reportedly pumped several billion dollars into the effort, ordering several million courses of each
at around $700 a...
Share This Article